AXGN - Earnings announcements

ALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the first quarter of 2026 on Tuesday, April 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available

ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event

ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a 6.0% increase over the second quarter of 2025.For the third quarter of 2025, gross margin was 76.6%, up from 74.9% for the third quarter of 2024, and up from 74.2% in the second quarter of 2025.Net income for the quarter was $0.7 million,

ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 third quarter financial results on Wednesday, October 29, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, archived replay, and presentation slides of t

ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the second quarter of 2024, and a 16.7% increase over the first quarter of 2025.For the second quarter of 2025, gross margin was 74.2%, up from 73.8% for the second quarter of 2024, and up from 71.9% in the first quarter of 2025.Net income for the quarter was $0.6

ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 second quarter financial results on Tuesday, August 5, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the

ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first quarter of 2024.Net loss for the quarter was $3.8 million, or $0.08 per share, compared to $6.6 million, or $0.15 per share for the first quarter of 2024.Adjusted net loss for the quart

ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visit

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1% for the fourth quarter compared to 74.6% for the fourth quarter of 2023.Net income for the quarter was $0.4 million, or $0.01 per share, compared to net loss of $3.9 million, or $0.09 per shar

ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the In

ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% in the third quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $4.1 million, or $0.10 per share in the third quarter of 2023.Adjusted

ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do s

ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023.In the second quarter of 2024, our gross margin decreased to 73.8%, down from 77.7% in the second quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $6.7 million, or $0.1

ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by

ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the same quarter of the previous year.Net loss for the quarter was $6.6 million, or $0.15 per share, compared to net loss of $7.1 million, or $0.17 per share in the fir

ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so

ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Results and Business Highlights Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the fourth quarter and grew mid-single digits versus the fourth quarter of 2022.The Company e

ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Inte

ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2023. Third Quarter Financial Results Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the third quarter and grew in the mid-single digit range versus the third quarter of 2022.The Company estimates that reve

ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may d

ALACHUA, Fla. and TAMPA, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2023. Second Quarter Financial Results and Business Highlights Revenue was $38.2 million during the second quarter, an increase of approximately 11% over the second quarter of 2022.The Company estimates that revenues from scheduled non-trauma procedures represented approximately half of total revenues during the second quarter and grew over 20% from the second quarter of 2022.The Company estimates th

ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2023 financial results on Monday, August 7, 2023 after the market closes. Axogen management will host an investment-community conference call and webcast at 4:30 p.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do

ALACHUA, Fla. and TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2023. First Quarter Financial Results and Business Highlights Net revenue was $36.7 million, an increase of 18% over the first quarter of 2022.Gross margin was 81.7%, compared to 82.1% in the first quarter of 2022.Net loss of $7.1 million, or $0.17 per share, compared to net loss of $11.5 million, or $0.27 per share in the first quarter of 2022.Adjusted net loss of $4.1 million, or $0.10 per share, co

ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (866) 682-6100 or use the direct dial-in number at (862) 298-0702. Those interested in listening to the conference call live via the Internet may do so b

ALACHUA, Fla. and TAMPA, Fla., March 14, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Results and Business Highlights Fourth quarter revenue was $36.2 million, a 17% increase compared to fourth quarter of 2021.*Gross margin was 83.0% for the fourth quarter compared to 82.8% in the fourth quarter of 2021.Net loss for the quarter was $5.4 million, or $0.13 per share, compared to net loss of $5.3 million, or $0.13 per share in th

ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do

ALACHUA, Fla. and TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2022. Third Quarter Financial Results 2022 and Business Highlights Net revenue was $37.0 million during the third quarter, an increase of 18% over the third quarter of 2021.*Gross margin was 83.3% for the quarter compared to 83.2% in the third quarter of 2021.Net loss for the quarter was $4.3 million, or $0.10 per share, compared to net loss of $7.1 million, or $0.17 per share in the third quarte

ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the November 8, 2022 conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Int

ALACHUA, Fla. and TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2022. Second Quarter 2022 and Business Highlights Net revenue was $34.5 million during the second quarter, an increase of 3% over the second quarter of 2021.Excluding revenue from Avive® Soft Tissue Membrane of $1.8 million in the second quarter of 2021, revenue in the second quarter of 2022 increased 9%. The company voluntarily suspended market availability of Avive on June 1, 2021.Gross margin was

Organizational updates are part of plan to bring additional focus on leveraging clinical data to accelerate market development and the pace of innovation Preliminary unaudited second quarter revenue of approximately $34.4 million Company will report full second quarter results on August 3, 2022. ALACHUA, Fla. and TAMPA, Fla., July 18, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced organizational updates and preliminary second quarter revenue. The company is making certain changes to its commercial organization designed to leverage the strength of its

ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2022. First Quarter 2022 and Business Highlights Net revenue was $31.0 million during the first quarter, matching the first quarter of 2021.Excluding Avive® revenue of $1.7 million in the first quarter of 2021, revenue in the first quarter of 2022 increased 6%. The company voluntarily suspended market availability of Avive Soft Tissue Membrane on June 1, 2021.Gross margin was 82.1% for the quarter com

ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so

ALACHUA, Fla. and TAMPA, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 and Business Highlights Net revenue was $31.5 million during the fourth quarter, a 3% decrease compared to fourth-quarter 2020 revenue of $32.5 million.Fourth quarter revenue includes $0.5 million from the reversal of a sales return reserve recorded in the second quarter of 2021 for Avive® Soft Tissue Membrane, for which the company voluntarily suspended ma

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2021. Third Quarter 2021 Financial Results and Recent Business Highlights Net revenue was $31.2 million during the quarter, a 7% decrease compared to third quarter 2020 revenue of $33.4 million. Prior-year revenue included approximately $3.3 million from procedures deferred from the first half of 2020 as a result of the initial impact of the COVID-19 pandemic, and approximately $1.5 million from

ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via t

ALACHUA, Fla. and TAMPA, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2021. Second Quarter 2021 Financial Results and Recent Business Highlights Net revenue was $33.6 million during the quarter, a 52% increase compared to second quarter 2020 revenue of $22.1 million.Gross margin was 78.9% for the quarter, compared to 74.7% one year ago. Gross margin would have been approximately 83.1% excluding the impact of a one-time charge of approximately $1.4 million reflecting th